Thrombotic microangiopathy in a patient with cancer of unknown origin
Keywords:
Thrombocytopenia, Microangiopathic Haemolytic Anaemia, Cancer With Unknown Primary Site, MetastaticAbstract
Cancer-associated thrombotic microangiopathy (CATM) consists of microangiopathic haemolytic anaemia, thrombocytopenia, and ischaemic end organ-damage in patients with a known or unknown primary malignancy. Its diagnosis is challenging, as it is sometimes confused with thrombotic thrombocytopenic purpura, which is the most common cause of thrombotic microangiopathy in healthy patients. CATM can be a manifestation of the malignancy itself or a chemotherapy-related complication, with these patients having a poor prognosis. A case is presented of a patient who developed CATM in the context of metastatic cancer with an unknown primary site.
Author Biographies
Alejandra Castillo Ramirez, Parc Sanitari sant Joan de Déu
Departamento de Medicina Interna y Urgencias, Parc Sanitari sant Joan de Déu, Sant Boi de Llobregat, Barcelona, España
José Burillo Lorente, Parc Sanitari sant Joan de Déu
Departamento de Medicina Interna y Urgencias, Parc Sanitari sant Joan de Déu, Sant Boi de Llobregat, Barcelona, España
Pablo Javier Marchena Yglesias, Parc Sanitari sant Joan de Déu
Departamento de Medicina Interna y Urgencias, Parc Sanitari sant Joan de Déu, Sant Boi de Llobregat, Barcelona, España
References
Govind Babu KG, Bhat GR. Cancer-associated thrombotic microangiopathy. Ecancermedicalscience. 2016;10:649.
https://doi.org/10.3332/ecancer.2016.649
Morton JM, George JN. Microangiopathic hemolytic anemia and thrombocytopenia in patients with cancer. J Oncol Pract. 2016;12:523-30.
https://doi.org/10.1200/JOP.2016.012096
Lechner K, Obermeier HL. Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases. Medicine (Baltimore). 2012;91:195-205.
https://doi.org/10.1097/MD.0b013e3182603598
Pisoni R, Ruggenenti P, Remuzzi G. Drug-induced thrombotic microangiopathy: incidence, prevention and management. Drug Saf. 2001;24:491-501.
https://doi.org/10.2165/00002018-200124070-00002
Richmond J, Gilbar P, Abro E. Gemcitabine-induced thrombotic microangiopathy. Intern Med J. 2013;43:1240-2.
https://doi.org/10.1111/imj.12261
Al-Nouri ZL, Reese JA, Terrell DR, Vesely SK, George JN. Druginduced thrombotic microangiopathy: A systematic review of published reports. Blood. 2015;125:616-8.
https://doi.org/10.1182/blood-2014-11-611335
Elliott MA, Letendre L, Gastineau DA, Winters JL, Pruthi RK, Heit JA. Cancer-associated microangiopathic hemolytic anemia with thrombocytopenia: An important diagnostic consideration. Eur J Haematol. 2010;85:43-50.
https://doi.org/10.1111/j.1600-0609.2010.01448.x
Rizvi MA, Vesely SK, George JN, Chandler L, Duvall D, Smith JW, et al. Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome. Transfusion. 2000;40:896-901.
https://doi.org/10.1046/j.1537-2995.2000.40080896.x
Francis KK, Kalyanam N, Terrell DR, Vesely SK, George JN. Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: A report of 10 patients and a systematic review of published cases. Oncologist. 2007;12:11-9.
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Todos los derechos reservados.
